Multiple sclerosis cost-effectiveness of therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
==Cost effectiveness== | ==Cost effectiveness== | ||
Given the [[morbidity]] and [[mortality]] associated with multiple sclerosis and the high cost of treating the acute attacks and [[disability]] of [[MS]] disease, treatment with [[Interferon beta-1a|IFN β-1a]] [[Subcutaneous|SC]] injection, [[Interferon beta-1b|IFNβ-1b]] [[Subcutaneous|SC injection]], and [[glatiramer acetate]] is relatively [[Cost-effectiveness|cost-effective]].<ref name="pmid19739877">{{cite journal |vauthors=Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM |title=Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis |journal=J Manag Care Pharm |volume=15 |issue=7 |pages=543–55 |date=September 2009 |pmid=19739877 |doi=10.18553/jmcp.2009.15.7.543 |url=}}</ref> | Given the [[morbidity]] and [[mortality]] associated with multiple sclerosis and the high cost of treating the acute attacks and [[disability]] of [[MS]] disease, treatment with [[Interferon beta-1a|IFN β-1a]] [[Subcutaneous|SC]] injection, [[Interferon beta-1b|IFNβ-1b]] [[Subcutaneous|SC injection]], and [[glatiramer acetate]] is relatively [[Cost-effectiveness|cost-effective]].<ref name="pmid19739877">{{cite journal |vauthors=Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM |title=Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis |journal=J Manag Care Pharm |volume=15 |issue=7 |pages=543–55 |date=September 2009 |pmid=19739877 |doi=10.18553/jmcp.2009.15.7.543 |url=}}</ref> Life time treatment of multiple sclerosis patients can cost as much as 2.2 million US dollar. Acute attacks and relapses can cause 12.870 dollars if it's sever, 1.847 dollars if it's moderate and 243 dollars if it's mild. controlling this attack can reduce the burden of [[MS]] disease. | ||
==References== | ==References== | ||
Revision as of 16:33, 4 March 2018
|
Multiple sclerosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple sclerosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Multiple sclerosis cost-effectiveness of therapy |
|
Multiple sclerosis cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Multiple sclerosis cost-effectiveness of therapy |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Cost effectiveness
Given the morbidity and mortality associated with multiple sclerosis and the high cost of treating the acute attacks and disability of MS disease, treatment with IFN β-1a SC injection, IFNβ-1b SC injection, and glatiramer acetate is relatively cost-effective.[1] Life time treatment of multiple sclerosis patients can cost as much as 2.2 million US dollar. Acute attacks and relapses can cause 12.870 dollars if it's sever, 1.847 dollars if it's moderate and 243 dollars if it's mild. controlling this attack can reduce the burden of MS disease.
References
- ↑ Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM (September 2009). "Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis". J Manag Care Pharm. 15 (7): 543–55. doi:10.18553/jmcp.2009.15.7.543. PMID 19739877.